SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR MVADS 2015

The drive for the new generation of vaccine therapies has precipitated a concurrent need for new and improved adjuvantation/delivery systems for these new vaccines. This new international conference will focus on updating the community on new adjuvant/delivery systems/technologies associated with developing modern vaccines strategies and vaccine research. There is now an urgent need for the development of these potent and safe adjuvants and delivery systems and MVADS 2015 will offer researchers a fresh forum to discuss this important topic in detail.

MVADS 2015 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups.

ADVISORY SCIENTIFIC PANEL

Local Organisers: Edmund J. Remarque (BPRC, Rijswijk, The Netherlands) and Ferry Ossendorp (Leiden University Medical Center, Leiden, The Netherlands)

Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)
Erik Lindblad (Brenntag Biosector, Copenhagen, Denmark)
Stein Lokstad (Brenntag Biosector, Copenhagen, Denmark)
Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)
Heather Davis (Pfizer Vaccine Research, Ottawa, Canada)
Derek O’Hagan (Novartis Vaccines, Cambridge, Massachusetts, USA)
Adriana Baz Morell (CSL Ltd, Melbourne, Australia)
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)
John Clements (Tulane University, New Orleans, Louisiana, USA)
Gwyn Davies (St. George’s, University of London, UK)
Nathalie Garcon (BIOASTER Technology Research Institute, Lyon, France)
Niranjan Sardesai (Inovio Pharmaceuticals, Blue Bell, Pennsylvania, USA)
Greg Glenn (Novavax Inc., Maryland, USA)
Virgil Schijns (Wageningen University, The Netherlands)
Gary Ott (Dynavax Inc., San Diego, California, USA)
Burkhard Becher (University of Zurich, Zurich, Switzerland)
Stephane Ascarateil (SEPPIC, Paris, France)
Geert Vanden Bossche (UNIVAC LLC, Belgium)
Steve Reed (IDRI, Seattle, USA)
Martin Bachmann (University of Zurich, Switzerland & University of Oxford, UK)
Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)
Nicolas Havelange (EVI, Heidelberg, Germany)
Jeffrey A. Hubbell (EPFL, Lausanne, Switzerland)

CONFERENCE SCOPE

Scientific Sessions:
Mechanistic Interpretations · Delivery · Formulation & Design · Modern Vaccines & Adjuvants · Safety · Regulation · Future Developments
Welcome to LUMC Leiden  
Ferry Ossendorp (University of Leiden, Leiden, The Netherlands)

SESSION 1:  
PLENARY SESSION

Moderator: Ferry Ossendorp (University of Leiden, Leiden, The Netherlands)

KEYNOTE:  
‘Antitumour vaccines’  
Kees Melief (Leiden University Medical Centre, Leiden, The Netherlands)

‘Designing the next generation of vaccine adjuvants’  
Derek O’Hagan (Novartis Vaccines, Cambridge, Massachusetts, USA)

‘Adjuvants for unmet needs’  
Steve Reed (IDRI, Seattle, Washington, USA)

‘Janssen ebola vaccine development update’  
Benoit Callendret (Janssen Vaccines, Leiden, The Netherlands)

Coffee Break & Poster Set-Up

SESSION 2:  
VACCINES

Moderator: Ed Remarque (BPRC, Rijswijk, The Netherlands)

‘Hapten- and peptide-conjugate vaccines: The importance of conjugate design and adjuvants’  
Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)

‘Clinical development of an oral vaccine to prevent Ebola virus infection’  
Sean N. Tucker (Vaxart Inc., South San Francisco, California, USA)

‘DNA vaccination and immunoprophylaxis for Ebola virus’  
Niranjan Y. Sardesai (INOVIO Inc., Plymouth Meeting, Pennsylvania, USA)

‘Developing novel malaria vaccine delivery platforms for induction of very high antibody responses: Towards clinical development’  
Sumi Biswas (University of Oxford, Oxford, UK)

‘Optimization of the process for making clinical supplies of an enveloped virus-like particle vaccine for cytomegalovirus’  
Marc Kirchmeier (VBI Vaccines, Cambridge, Massachusetts, USA)

Lunch Break, Posters, Exhibits

SESSION 3:  
SPECIAL SESSION: BIOMARKERS OF VACCINE/ADJUVANT POTENCY AND SAFETY (BVAPS)

Moderator: Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

‘Introduction to BVAPS special session’  
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

‘Smart data in vaccine research’  
Nathalie Garcon (BioAster, Lyon, France)

‘The ink spots and signatures of adjuvants’  
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

‘Transcriptional profiling reveals that IL-18 and IFN-alpha signalling are crucial mediators in the immune response initiated by ISCOMATRIX® adjuvant’  
Anne Walter (CSL Ltd, Melbourne, Victoria, Australia)

‘Molecular biomarkers of human skin vaccination’  
Behazine Combiadire (Centre d’Immunologie et des Maladies Infectieuses Cimi, Paris, France)

‘Signature of adjuvant systems: From human to mouse models’  
Arnaud Didierlaurent (GlaxoSmithKline Vaccines, Rixensart, Belgium)

‘Biomarkers in tuberculosis’  
Tom M H Ottenhoff (Leiden University Medical School, Leiden, The Netherlands)

Tea Break, Posters, Exhibits

SESSION 4:  
VACCINES/ADJUVANTS DELIVERY

Moderator: Nathalie Garcon (BioAster, Lyon, France)

‘Induction of protective immune response in mice by intramuscular, intranasal and combined IM and IN delivery of norovirus VLP candidate vaccine’  
Maria Malm, Kirsi Tamminen, Timo Vesikari and Vesna Blazevic (University of Tampere, Tampere, Finland)

‘PPD: A gold standard adjuvant that was never adopted clinically but should be revisited’  
Peter Lachmann (University of Cambridge, Cambridge, UK)

‘Insights into the delivery of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: Formulation optimization, biodistribution and immunogenicity in comparison to a licensed protein vaccine’  
Anne Endmann, Detlef Oswald, Oliver Riede, Eduard G. Talman, Roelien E. Vos, Matthias Schroff, Christiane Kleuss, Marcel H.J. Ruiters and Christiane Juhls (MOLOGEN AG, Berlin, Germany)

‘Adjuvanted peptide-loaded virosomes as an influenza T-cell vaccine’  
Peter Soema, Sietske Rosendahl Huber, Geert-Jan Willems, Wim Jiskoot, Gideon Korsten and Jean-Pierre Amorij (Intravacc, Buitenvoet, The Netherlands)

‘One-shot sustained release nanoparticle vaccines’  
Sarah Hook (University of Otago, Dunedin, New Zealand)

‘DNA vaccine delivery platform and adjuvant systems’  
Luigi Aurisicchio (Takis Biotech, Rome, Italy)

MVADS 2015 Welcome Reception & Poster Session

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Advisory Scientific Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 17th April 2015. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 17th April 2015.
SESSION 5: MUCOSAL/INTRANASAL

Moderator: Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

‘Vaccines and adjuvants for mucosal immunity’
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

‘Induction of mucosal memory with adjuvants’
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)

‘Vaccines and adjuvants for mucosal immunity’
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

‘Vaccines and adjuvants for mucosal immunity’
Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

Moderator: Ali Harandi (University of Gothenburg, Gothenburg, Sweden)

‘Antigen formulation with a novel combination adjuvant mediates the induction of long-term immune memory and disease prevention’
Sylvia van Drunen Little-van den Hurk (VIDO-Intervax, University of Saskatchewan, Saskatoon, Canada)

‘Role of adjuvant in inducing functional antibody responses’
Indresh K. Srivastava (ProteinsSciences Inc., Meriden, Connecticut, USA)

‘H7N9 influenza T cell epitopes similar to human sequences are less immunogenic and may induce Treg-mediated tolerance: Implications for vaccine design’
Rui Liu, Leonard Moise, Ryan Tassone, Andreas H. Gutierrez, Kotou Sangare, Loren Fast, William Martin and Anne S. De Groot (EpVax Inc./University of Rhode Island, Providence, Rhode Island, USA)

SESSION 6: SPECIAL SESSION: VACCINE FORMULATIONS FOR HIV VACCINES

Moderator: Dennis Christensen (SSI, Copenhagen, Denmark)

‘HIV-Env-based adjuvanted vaccines overview’
Robin Shattock (Imperial College, London, UK)

‘Overview on clinical evaluation of HIV-Env-based adjuvanted vaccines’
Julie McElrath (Fred Hutchinson Cancer Research Center, Seattle, Washington, USA)

‘Overview of the HIV vaccine adjuvant pipeline: Gates Foundation perspective’
Magda Moutaftsi (Bill & Melinda Gates Foundation, Seattle, Washington, USA)

‘Overview of the HIV vaccine adjuvant pipeline: NIH perspective’
Cesar Boggiano (NIH, Bethesda, Maryland, USA)

‘How can IL-4R antagonist adjuvanted HIV mucosal/systemic prime-boost vaccination strategy induce high avidity HIV-specific T and B cell immunity’
Charan Ranasinghe, Megat Abd Hamid, Matthew Worley, Alice Ng, Robert Center and Ronald Jackson (The Australian National University, Acton, ACT, Australia)

‘Development of consensus gene vaccines for drug-resistant HIV’
Maria Issagoulantis (Karolinska Institutet, Stockholm, Sweden / Riga Stradins University, Riga, Latvia)

Lunch Break, Posters, Exhibits

SESSION 7: MECHANISMS, FORMULATION & DESIGN

Moderator: Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)

‘The epitope dilution phenomenon: Lessons learnt from a polymorphic malaria vaccine candidate (AMA1) and applicability to polymorphic vaccine antigens’
Edmond J. Remarque (Biomedical Primate Research Centre, Rijswijk, The Netherlands)

‘Rational design of TLR4 agonist based combination adjuvants’
Darrick Carter (IDRI, Seattle, Washington, USA)

‘Antigen formulation with a novel combination adjuvant mediates the induction of long-term immune memory and disease prevention’
Sylvia van Drunen Little-van den Hurk (VIDO-Intervax, University of Saskatchewan, Saskatoon, Canada)

‘Role of adjuvant in inducing functional antibody responses’
Indresh K. Srivastava (ProteinsSciences Inc., Meriden, Connecticut, USA)

‘TNF α blockade does not influence IL-1β and IL-18 secretion by human whole blood stimulated with LPS and aluminium hydroxide, but abrogates IFNγ responses’
Karen E. Malone, M. Moerland, W. Grievink, J. Reijers, J. Burggraaf and C. Kluft (Good Biomarker Sciences / Centre for Human Drug Research, Leiden, The Netherlands)

Tea Break, Posters, Exhibits

SESSION 8: ADJUVANTS

Moderator: Steve Reed (IDRI, Seattle, Washington, USA)

‘Adjuvant data base project: Can we predict vaccine MOA and/or side effect?’
Ken J. Ishii (NIBIO/University of Osaka, Osaka, Japan)

‘Development and adjuvant activity of Alum-based TLR ligand formulation’
Chris Fox (IDRI, Seattle, Washington, USA)

‘Comparative evaluation of the Cationic Adjuvant Formulation CAF09 versus CAF01 in non-human primates’
Frank A.W. Verreck, V. Sommandas, Sumera Y. Younis, Claudia C. Sombroeck, Richard A.W. Vervenne, Saskia Burm, Jennifer Veth, Jeffrey Bajramovic, K.S. Kerkhofs, Clemens Kocken, Peter L. Andersen and Dennis Christensen (Biomedical Primate Research Centre, Rijswijk, The Netherlands / Statens Serum Institute, Copenhagen, Denmark)

‘Preclinical and clinical experience with the cationic lipid adjuvant, DC-Cholesterol’
Jean Haensler (Sanofi Pasteur, Marcy l’Etoile, France)

‘A versatile and potent adjuvant solution’
Peter Bonde Jorgensen and Stein Loksted (Brenntag Biosector, Frederikssund, Denmark)

‘Montanide vaccine adjuvants, mechanisms of action and delivery systems for vaccines formulations’
Stephane Ascarateil (SEPPIC, Paris, France)

‘New adjuvants for developing countries’
Isaisas Raw, W. Quintilio, C. Myiaki, A. Precioso and P.L. Ho (Butantan Institute, Sao Paulo, Brazil)
**SESSION 9: SAFETY, EFFICACY & TESTING**

Moderator: Peter Lachmann (University of Cambridge, Cambridge, UK)

‘Accelerated vaccine design and efficacy testing using the IVAX toolkit’
Frances Terry, Leonard Moise, Andres Gutierrez, Rui Liu, Ryan Tassone, Rebecca Martin, William Martin and Anne S. De Groot (Epivax Inc./University of Rhode Island, Providence, Rhode Island, USA)

‘Better vaccines through packaging’
Alan Shaw (Independent, USA)

‘Safety and tolerability evaluation of the use of Montanide ISA™ 51 as vaccine adjuvant: a systematic review’
Eva van Doorn, Heng Liu, Anike Huckriede and Eelko Hak (University of Groningen, Groningen, The Netherlands)

‘A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile’
Regina Heidenreich (CureVac GmbH, Tubingen, Germany)

‘Efficacy of ACI-35, a liposomal anti-p[ospho Tau vaccine in an Adeno-associated virus (AAV) Tau P301S mouse model of Alzheimer’s disease’
M. Vukicevic, M. Phihgren, V. Gafner, K. Piorkowska, N. Chuard, V. Giriens, P. Valdes, S. Nazeeruddin, P. Colin, A. Pfeifer, B. Schneider and A. Muhs (AC Immune SA, Lausanne, Switzerland)

‘Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination’
Vincent Serra (Abivax, Paris, France)

Coffee Break, Posters, Exhibits

**SESSION 10: SKIN DELIVERY & ALTERNATES**

Moderator: Derek O’Hagan (Novartis Vaccines, Cambridge, Massachusetts, USA)

‘Microneedles for dermal delivery of vaccines’
Joke Bowstra (Leiden/Amsterdam Center for Drug Research, The Netherlands)

‘The use of TLR 7/8 agonists as vaccine adjuvants and microneedle delivery systems to enhance vaccine responses’
Mark Tomai (3M Drug Delivery Systems, St. Paul, Minnesota, USA)

‘Laser-assisted intradermal delivery of Xc11-specific fusion vaccines induces potent anti-tumor response’
Dorothea Terhorst, Elmlia Lechat, Even Fossum, Bjarne Bogen, Sandrine Henri and Bernard Malissen (BPRC, Rijswijk, The Netherlands)

‘Alternative delivery of a thermostable inactivated polio vaccine’
Heleen Kraan, Ivo Ploemen, Gijsbert van de Wijdeven, Gideon Kersten and Jean-Pierre Amorij (Intravacc, Bilthoven, The Netherlands)

Lunch Break, Posters, Exhibits

* This provisional programme is correct at the time of printing, however the organisers reserve the right to amend this version of the programme in the interim. A final programme will be available late April/early May 2015.

**SESSION 11: SYNTHETIC CANCER VACCINES**

Moderator: Ferry Ossendorp (Leiden University Medical Centre, Leiden, The Netherlands)

‘Liposome formulated peptide cancer vaccines’
Eleni Varipataki (LACDR, Leiden University, Leiden, The Netherlands)

‘Synthetic adjuvants’
Dimitri Filippow (University Leiden, Leiden, The Netherlands)

‘TLR and NLR targeted cancer vaccines’
Gis Gom (Leiden University Medical Centre, Leiden, The Netherlands)

‘Conjugated peptide cancer vaccines: towards a clinical study’
Ferry Ossendorp (Leiden University Medical Centre, Leiden, The Netherlands)

Tea Break, Posters Breakdown, Exhibits Breakdown

**SESSION 12: CLOSING SESSION**

Moderator: Ed Remarque (BPRC, Rijswijk, The Netherlands)

‘In vivo imaging of gene reporter expressing in tracing gene delivery and specific immune responses in gene immunization’
Stefan Petkov (Karolinska Institutet, Stockholm, Sweden)

‘Direct quantification and characterisation of virions and adjuvant particles with Tunable Resistive Pulse Sensing (TRPS)’
Dimitri Aubert (Izon Science, Oxford, UK)

‘Enhanced productivity in developing and manufacturing vaccines using monolithic columns’
Lidija Urbas (BIA Separations d.o.o., Ajdovscina, Slovenia)

Title to be confirmed
Jeff Hubbell (EPFL, Lausanne, Switzerland)

Title to be confirmed
Greg Glen (Novavax Inc., Rockville, Maryland, USA)

Title to be confirmed
Gale Smith (Novavax Inc., Rockville, Maryland, USA)

Title to be confirmed
Linda Stertman and Karin Lowgren (Novavax AB, Stockholm, Sweden)

**SESSION 13: LATEBREAKER SESSION**

Moderator: To be confirmed

Latebreaker abstracts are called for this session.

Abstracts should be submitted to:
John Herriot
MVADS 2015 Secretariat
jherriot@meetingsmgmt.u-net.com

The closing date for latebreaker abstracts is Friday 1st May 2015.

**LATE-BREAKER ORAL AND POSTER ABSTRACTS**

The Advisory Scientific Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 17th April 2015. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to:
jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 17th April 2015.
REGISTRATION

Delegates should register for MVADS 2015 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the MVADS 2015 Conference Manager – Caroline Sumner at Meetings Management. The MVADS 2015 Conference Registration Desk will be open from 7.30am on Monday 18th May 2015.

Delegates can also register securely on-line at:
www.meetingsmanagement.com/mvads_2015

VENUE & ACCOMMODATION

MVADS 2015 will be held at:
Leiden University Medical Center, Leiden, The Netherlands

Please contact the Conference Manager for this additional price.

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 17th April 2015. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Table Top Exhibition facilities at MVADS 2015 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the MVADS 2015 delegate pack is priced at £450. Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at MVADS 2015 should be directed to John Herriot at Meetings Management (E-mail: jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: Literature for distribution to MVADS 2015 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at MVADS 2015. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The MVADS 2015 Advisory Scientific Panel and the MVADS 2015 Conference Organizers reserve the right to alter any part of the published conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization's library up to date. The cost of providing this non-attendee package is £395 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner MVADS 2015 Conference Manager:
MVADS 2015 Conference Secretariat, Meetings Management
The Old Dairy Tower, Peper Harow Park, Godalming, Surrey GU8 6BD, United Kingdom.
Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
E-mail: csumner@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Advisory Scientific Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 17th April 2015. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 17th April 2015.
Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname ................................. Initials ......................................... Title ........................................
Organization ................................ Address ........................................
.................................................................................................................................
.................................................................................................................................
Country .................................... Telephone ......................................... Fax .................................
E-mail (plain type or print): .................................................................

If you are an EC business please state your VAT registration number: .................................................................

Disabled (please state any special needs): ................................................................. Special diet (please state requirements): .................................................................

REGISTRATION FEES

<table>
<thead>
<tr>
<th>Speaker/Delegate Registration Fees:</th>
<th>(NOTE THAT FEES ARE IN UK £ STERLING)</th>
<th>DELEGATE REGISTRATION FORMS NOT DULLY &amp; FULLY COMPLETED WILL NOT BE VALID</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Speaker Registration (submitted oral/poster papers)</td>
<td>£645.00</td>
<td>Amount Due (£ Sterling)</td>
</tr>
<tr>
<td>(Payment must be received before Friday 6th March 2015)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Reduced Early Bird Registration</td>
<td>£760.00</td>
<td></td>
</tr>
<tr>
<td>(Payment must be received before Friday 6th March 2015)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Full Registration</td>
<td>£875.00</td>
<td></td>
</tr>
<tr>
<td>(Payment received after Friday 6th March 2015)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Student Registration</td>
<td>Price on application</td>
<td></td>
</tr>
</tbody>
</table>

Table Top Exhibits/Delegate Pack Inserts

| Table Top Exhibit (I am registered to attend) | £1500.00 | |
| Table Top Exhibit (I am NOT registered to attend) | £2500.00 | |
| Delegate Pack Insert | £450.00 | |

For those Unable to Attend

| Set(s) of MVADS 2015 materials | @ £395.00 (per set) | £ |

Total Amount Payable

£

Registration fees include admission to all conference sessions, morning and afternoon refreshments and lunches on the 18th, 19th and 20th May 2015.

PAYMENT

☐ I enclose a cheque for £....................... made payable to Meetings Management. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote MVADS 2015 on the reverse of the cheque.)

☐ I have made a payment by bank transfer (quoting MVADS 2015 on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK:

UK Pounds Sterling Account: Meetings Management 0040614335, IBAN GB02BARC20353540614335 SWIFTBIC BARCB22

US Dollar Account: Meetings Management 53209211, IBAN GB87BARC20353553209211 SWIFTBIC BARCGB22

Euro Account: Meetings Management 59179600, IBAN GB91BARC20353559179600 SWIFTBIC BARCGB22

All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 10TH APRIL 2015. LATE PAYMENT AFTER FRIDAY 10TH APRIL 2015 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).

☐ I would like to pay £....................... by credit card (VISA/MasterCard/AMEX Express only accepted).

Card no. ................................................................. 3 Digit Security Code (AMEX: 4 Digits) .................................................................

Expiry Date ................................................................. Registered Card Address .................................................................

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 10th April 2015 will be refunded in full less an administrative charge of £150 per person. Refunds will not be possible if a cancellation is received after Friday 10th April 2015. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees.

VAT No. 591 617618

Signature ................................................................. Date .................................................................

PLEASE RETURN THIS FORM TO:

MVADS 2015 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT
The Old Dairy Tower, Peper Harow Park, Godalming, Surrey GU8 6BD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: csumner@meetingsmgmt.u-net.com